Abstract
Bradykinin concentrations and the ratio of bradykinin to its stable metabolite BK1–5 (RPPGF) were significantly increased in patients presenting with angiotensin-converting enzyme (ACE) inhibitor-associated angioedema compared to ACE inhibitor-treated controls. Cleavage of high molecular weight kininogen was not increased in patients with ACE inhibitor-associated angioedema, indicating that increased bradykinin concentrations result from decreased degradation.
Publication types
-
Letter
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Angioedema / blood*
-
Angioedema / chemically induced*
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects*
-
Bradykinin / blood*
-
Enalapril / adverse effects
-
Female
-
Humans
-
Kininogen, High-Molecular-Weight / blood
-
Lisinopril / adverse effects
-
Male
-
Middle Aged
-
Peptide Fragments / blood*
-
Quinapril / adverse effects
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Kininogen, High-Molecular-Weight
-
Peptide Fragments
-
bradykinin (1-5)
-
Enalapril
-
Lisinopril
-
Quinapril
-
Bradykinin